세포 및 유전자 치료 임상시험 시장 - 세계 예측(2026-2032년)

The Cell & Gene Therapy Clinical Trials Market is projected to grow by USD 25.92 billion at a CAGR of 12.41% by 2032.

Cell and gene therapy clinical trials are reshaping advanced therapeutics by moving beyond symptom management toward potentially disease-modifying and, in select indications, curative interventions. The field spans autologous and allogeneic cell therapies, viral and non-viral gene delivery, gene editing, RNA-enabled approaches, and ex vivo manufacturing models for oncology, rare diseases, hematology, ophthalmology, neurology, immunology, and metabolic disorders. Regulatory momentum has strengthened as agencies refine guidance on long-term follow-up, chemistry, manufacturing, and controls, vector shedding, comparability, potency assays, and patient safety monitoring. At the same time, trial sponsors are navigating complex operational demands, including site qualification, specialized cold chain logistics, leukapheresis coordination, individualized manufacturing slots, decentralized patient monitoring, and high-intensity pharmacovigilance. The clinical development environment is also shaped by verified trends across public trial registries, peer-reviewed evidence, regulatory guidance, and health-system adoption of precision medicine, including growing use of genomic testing, biomarker-led enrollment, and structured long-term follow-up for advanced therapy medicinal products. The most competitive clinical development strategies now combine rigorous translational science with scalable manufacturing design, real-world evidence planning, biomarker-led patient selection, and early engagement with regulators, payers, investigators, and patient advocacy networks. As cell and gene therapy clinical trials expand across regions and therapeutic areas, success increasingly depends on balancing scientific innovation with reproducibility, ethical governance, patient access, and durable evidence generation.

Transformative Shifts in the Clinical Trial Landscape

The cell and gene therapy clinical trial landscape is undergoing transformative change as development models shift from conventional, site-centric drug trials toward integrated therapeutic platforms requiring precise biological characterization, high-touch patient management, and digitally enabled oversight. Trial design is becoming more adaptive, particularly in rare diseases and oncology where small patient populations, urgent unmet needs, and biomarker-defined eligibility demand flexible evidence strategies. Regulators have increasingly emphasized long-term safety surveillance for integrating vectors, genome editing technologies, and products with durable biological activity, making post-treatment follow-up a central component of protocol architecture. Manufacturing has also become a defining clinical variable, with comparability studies, chain-of-identity controls, release testing, sterility assurance, and potency assays influencing enrollment timelines and treatment consistency. The expansion of allogeneic cell therapy platforms, in vivo gene therapies, and targeted delivery systems is prompting new approaches to immune management, dosing, retreatment evaluation, and risk mitigation. In parallel, clinical trial networks are investing in specialized investigator training, apheresis and infusion capabilities, cryogenic storage, genetic counseling, and adverse event management protocols for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, insertional mutagenesis, vector-related immunogenicity, and off-target editing risk. These shifts are pushing stakeholders to build more resilient, interoperable, and patient-centered development ecosystems capable of supporting evidence generation from first-in-human studies through long-term real-world follow-up.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing cell and gene therapy clinical trials by improving how complex biological, clinical, imaging, genomic, and manufacturing data are interpreted across the development lifecycle. In protocol design, AI-enabled analytics can support feasibility assessment, inclusion and exclusion criteria optimization, and identification of trial sites with relevant patient populations and operational readiness. In patient recruitment, machine learning models can help screen electronic health records, registry data, molecular diagnostic results, and referral patterns to identify potentially eligible participants, especially in rare diseases where traditional recruitment pathways are limited. AI is also being applied to biomarker discovery, vector design support, immune response modeling, dose-response exploration, digital pathology, imaging analysis, and prediction of manufacturing deviations. During trial execution, advanced analytics can enhance remote monitoring, detect safety signals, support risk-based quality management, and streamline data review across decentralized or hybrid study models. Verified implementation remains strongest where datasets are curated, interoperable, and clinically annotated, and where algorithms can be tested against protocol-defined outcomes, safety events, and manufacturing quality attributes. However, the cumulative impact of AI depends on transparent validation, bias assessment, privacy-preserving data governance, regulatory traceability, cybersecurity, and human clinical oversight. For cell and gene therapy trials, AI is most valuable when it augments scientific decision-making, strengthens evidence quality, accelerates operational workflows, and supports patient safety without replacing expert judgment.

Key Regional Insights Across Global Trial Ecosystems

Asia-Pacific is becoming increasingly important for cell and gene therapy clinical trials due to its expanding hospital infrastructure, large genetically diverse patient populations, rising use of molecular diagnostics, and growing regulatory engagement across advanced therapy frameworks. Countries in the region are strengthening clinical trial ecosystems through investments in regenerative medicine, oncology research, rare disease diagnostics, digital health, and biomanufacturing capacity, with Japan, China, South Korea, Australia, India, and Singapore contributing distinctive capabilities in regenerative medicine regulation, oncology studies, early-phase trials, and translational science. Europe offers a highly structured advanced therapy medicinal product environment, with established regulatory science, cross-border research collaboration, strong ethics oversight, national health data initiatives, transplantation expertise, and growing emphasis on harmonized health technology assessment and long-term evidence generation. North America remains a leading hub for early-stage and pivotal cell and gene therapy trials, supported by mature regulatory pathways, specialized academic medical centers, experienced trial sites, advanced manufacturing networks, genomic medicine programs, and strong patient advocacy participation. Latin America is gaining relevance as clinical research capabilities expand in major urban centers, with opportunities linked to oncology, hematology, immunology, and inherited disease programs, although infrastructure variability, reimbursement complexity, regulatory timelines, and temperature-controlled logistics remain important considerations. Africa presents long-term potential for gene therapy and cell therapy research through its genetic diversity, infectious disease expertise, newborn screening expansion, and growing clinical research networks, but broader participation requires sustained investment in diagnostics, regulatory capacity, cold chain logistics, workforce training, ethics governance, and equitable access frameworks. The Middle East is investing in precision medicine, national genomics programs, oncology centers, and specialized healthcare infrastructure, positioning selected countries as emerging destinations for advanced therapy research, regional referral care, and inherited disease-focused clinical development where trial readiness continues to mature.

Key Group Insights Shaping Advanced Therapy Development

NATO member countries, while not a healthcare regulatory bloc, include many nations with mature clinical research systems, robust biosecurity standards, advanced hospital networks, and resilient medical infrastructure that support complex trial execution, cross-border collaboration, emergency preparedness, and critical biopharmaceutical supply chain planning. G7 countries continue to anchor high-complexity cell and gene therapy trials through established regulatory systems, translational research capacity, advanced hospitals, long-term safety follow-up infrastructure, rare disease networks, and strong pharmacovigilance systems. BRICS countries contribute substantial patient diversity, expanding biomedical capabilities, and strong interest in domestic innovation, with China, India, and Brazil particularly relevant for scale, scientific talent, clinical research networks, and biomanufacturing development, while regulatory alignment, ethics standardization, and manufacturing consistency remain decisive. The European Union provides one of the most defined regulatory environments for advanced therapy medicinal products, supported by centralized scientific assessment, clinical trial regulation harmonization, pharmacovigilance requirements, cross-border research collaboration, and shared priorities around real-world evidence and health technology assessment. ASEAN is strengthening its role in cell and gene therapy clinical trials through expanding clinical research infrastructure, regional regulatory cooperation, growing biomedical investment, and increasing focus on oncology, rare disease diagnosis, and regenerative medicine. The region's diverse populations and improving hospital networks make it strategically relevant, although harmonized standards, advanced manufacturing access, and specialized site capabilities remain critical priorities. The GCC is advancing precision medicine and advanced therapy readiness through national genomics initiatives, tertiary care investment, digital health adoption, and growing interest in oncology and inherited disease programs, creating opportunities for regional clinical trial participation where regulatory clarity, specialized workforce capacity, and sustainable patient access models continue to mature.

Key Country Insights for Cell and Gene Therapy Trials

China has rapidly expanded cell and gene therapy clinical research, driven by large patient access, hospital investment, regulatory modernization, oncology specialization, and strong activity in gene editing-related science, while continued attention to trial quality, follow-up, and manufacturing comparability remains essential. The United States remains central to cell and gene therapy clinical trials due to its extensive regulatory experience, specialized academic and community oncology networks, rare disease advocacy ecosystem, public clinical trial infrastructure, and concentration of advanced manufacturing and translational research capabilities. Japan offers a distinctive regenerative medicine framework, high-quality clinical infrastructure, structured safety oversight, and strong experience in advanced therapy regulation. India is gaining attention due to its patient diversity, cost-efficient clinical operations, genomics initiatives, expanding hospital networks, and emerging biomanufacturing capabilities, with continued need for specialized site training, diagnostic access, and regulatory consistency. Germany combines robust biomedical research, hospital infrastructure, transplantation expertise, and manufacturing capabilities, making it highly relevant for advanced therapy trials. The United Kingdom maintains a strong position through advanced therapy regulatory expertise, national health data assets, genomics programs, adaptive trial capabilities, and specialist clinical centers. Australia is valued for efficient clinical trial start-up pathways, high-quality healthcare systems, early-phase research capabilities, and strong alignment with international good clinical practice standards. France supports cell and gene therapy development through academic medical networks, rare disease infrastructure, cell therapy expertise, and strong regulatory oversight. South Korea is advancing rapidly through biomanufacturing investment, hospital-based innovation, digital health infrastructure, and strong policy support for advanced biotherapeutics. Italy and Spain contribute experienced clinical sites, transplantation expertise, oncology networks, rare disease programs, and active academic research environments across advanced therapies. Canada supports advanced therapy research through strong academic hospitals, clinical trial quality standards, genomics initiatives, and growing biomanufacturing programs. Russia has scientific capabilities and patient population depth, but international trial participation is shaped by geopolitical, regulatory, supply chain, and operational constraints. Brazil is a major Latin American clinical research contributor with established tertiary centers, oncology expertise, hematology capabilities, and increasing interest in cell therapy, although operational timelines and access pathways require careful planning. Mexico is expanding clinical research participation, particularly in large metropolitan healthcare systems, while continued progress depends on specialized site readiness, regulatory predictability, referral pathways, and advanced logistics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated clinical development strategies that align scientific rationale, manufacturing feasibility, regulatory expectations, and patient access planning from the earliest trial stages. Protocols should be designed around validated biomarkers, clearly defined endpoints, robust safety monitoring, and long-term follow-up frameworks that address durability, delayed adverse events, immune responses, vector-related risks, and real-world outcomes. Sponsors and research networks should invest in qualified sites with proven capabilities in apheresis, cell handling, infusion, cryogenic storage, genetic counseling, emergency management, and protocol-specific training. Manufacturing strategy should be treated as a core clinical risk area, with strong chain-of-identity and chain-of-custody controls, release testing readiness, comparability planning, contamination prevention, validated shipping lanes, and contingency capacity. Digital tools and AI-enabled analytics should be adopted selectively where validation, auditability, data privacy, cybersecurity, and regulatory acceptance are clear. Patient recruitment should be strengthened through registries, genetic testing partnerships, referral education, newborn screening linkages where appropriate, advocacy engagement, and culturally appropriate informed consent materials. Leaders should also build regional diversification strategies that balance access to eligible patients with regulatory maturity, site quality, logistics, ethics oversight, and long-term follow-up feasibility. Finally, early payer and health system engagement is essential to align clinical evidence generation with future access requirements, particularly for therapies with high upfront complexity and long-term value claims.

Research Methodology

The research methodology for evaluating cell and gene therapy clinical trials should combine primary and secondary research, regulatory intelligence, clinical trial registry analysis, peer-reviewed literature review, and expert validation. Primary inputs should include interviews with clinical investigators, regulatory specialists, manufacturing leaders, trial operations professionals, ethics committee members, patient advocacy representatives, and healthcare decision-makers. Secondary research should draw from official regulatory guidance, public clinical trial databases, scientific journals, conference proceedings, public health agency publications, treatment guidelines, pharmacovigilance resources, and international good clinical practice standards. Data triangulation should be used to validate trends across therapeutic areas, modalities, geographies, trial phases, operational models, patient populations, and safety considerations. The methodology should examine protocol design, endpoint selection, patient eligibility, recruitment dynamics, site capabilities, manufacturing dependencies, logistics, long-term follow-up requirements, digital technology adoption, and real-world evidence planning. Quality control should include source verification, consistency checks, expert review, and exclusion of unsupported claims, market sizing, market share, and forecasting assumptions. Because the field is evolving rapidly, continuous monitoring of regulatory updates, clinical holds, safety communications, new guidance documents, clinical trial amendments, and trial design innovations is essential for maintaining analytical accuracy.

Conclusion

Cell and gene therapy clinical trials are entering a more mature phase defined by scientific precision, operational complexity, regulatory scrutiny, and global expansion. The next stage of progress will depend on the ability to generate durable clinical evidence while ensuring patient safety, manufacturing consistency, ethical transparency, and equitable access. Regions and countries with strong regulatory systems, advanced clinical infrastructure, specialized workforce capacity, reliable diagnostics, and integrated data capabilities are best positioned to support high-quality development. Artificial intelligence, decentralized monitoring, molecular diagnostics, and real-world evidence will continue to influence trial efficiency, but their value will depend on validation, governance, and clinical relevance. For industry leaders, the strategic priority is no longer simply initiating trials faster; it is building resilient ecosystems that can manage individualized therapies, complex biology, long-term follow-up, and evolving access expectations. Organizations that align innovation with execution discipline will be better prepared to advance cell and gene therapy clinical trials from experimental promise to meaningful patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell & Gene Therapy Clinical Trials Market, by Therapy Type

• 7.1. Introduction
• 7.2. Cell Therapy
• 7.3. Gene Therapy
• 7.4. Tissue Engineered Products

8. Cell & Gene Therapy Clinical Trials Market, by Delivery Method

• 8.1. Introduction
• 8.2. Non-Viral Vector
  • 8.2.1. Electroporation
  • 8.2.2. Lipid Nanoparticle
• 8.3. Viral Vector
  • 8.3.1. Adeno-Associated Virus
  • 8.3.2. Adenoviral
  • 8.3.3. Retroviral

9. Cell & Gene Therapy Clinical Trials Market, by Trial Phase

• 9.1. Introduction
• 9.2. Phase I
• 9.3. Phase II
• 9.4. Phase III

10. Cell & Gene Therapy Clinical Trials Market, by Therapy Source

• 10.1. Introduction
• 10.2. Autologous Therapies
• 10.3. Allogeneic Therapies

11. Cell & Gene Therapy Clinical Trials Market, by Manufacturing Type

• 11.1. Introduction
• 11.2. In-House Manufacturing
• 11.3. Outsourced Manufacturing

12. Cell & Gene Therapy Clinical Trials Market, by End User

• 12.1. Introduction
• 12.2. Pharmaceutical Companies
• 12.3. Biotechnology Companies
• 12.4. Academic & Research Institutes
• 12.5. Contract Research Organizations
• 12.6. Government & Non-profit Organizations

13. Cell & Gene Therapy Clinical Trials Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Cell & Gene Therapy Clinical Trials Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Cell & Gene Therapy Clinical Trials Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Advanced Clinical LLC
• 17.2. Allucent Holdings, Inc.
• 17.3. Almac Group Limited
• 17.4. BioAgilytix Labs, LLC
• 17.5. BioCentriq LLC
• 17.6. Caidya Group, Inc.
• 17.7. Catalent, Inc.
• 17.8. Charles River Laboratories International, Inc.
• 17.9. ClinChoice Inc.
• 17.10. CTI Clinical Trial and Consulting Services, Inc.
• 17.11. Frontage Laboratories, Inc.
• 17.12. ICON plc
• 17.13. IQVIA Holdings Inc.
• 17.14. KCR S.A.
• 17.15. Labcorp Holdings Inc.
• 17.16. Lonza Group AG
• 17.17. Medpace Holdings, Inc.
• 17.18. Miltenyi Biotec B.V. & Co. KG
• 17.19. Novotech Health Holdings Pte. Ltd.
• 17.20. Parexel International Corporation
• 17.21. Pharmaron Beijing Co., Ltd.
• 17.22. PPD, Inc.
• 17.23. Precision for Medicine, Inc.
• 17.24. Samsung Biologics Co., Ltd.
• 17.25. Syneos Health, Inc.
• 17.26. Takara Bio Inc.
• 17.27. Thermo Fisher Scientific Inc.
• 17.28. Veristat, LLC
• 17.29. Worldwide Clinical Trials Holdings, Inc.
• 17.30. WuXi AppTec Co., Ltd.